Sarkis Solange, Chamard Chloé, Johansen Bianca, Daien Vincent, Michon Frederic
Institute for Neurosciences of Montpellier, Univ Montpellier, Institut national de la santé et de la recherche médicale (INSERM), Montpellier, France.
Laboratoires Théa, Clermont-Ferrand, France.
Front Med (Lausanne). 2025 Mar 26;12:1527319. doi: 10.3389/fmed.2025.1527319. eCollection 2025.
Glaucoma, a leading cause of irreversible blindness, represents a significant challenge in ophthalmology. This review examines recent advancements in glaucoma treatment, focusing on innovative medications and creative strategies. While new agents offer promising methods for lowering intraocular pressure (IOP), they also pose challenges related to efficacy and side effects. Alongside IOP reduction, emerging neuroprotective approaches are being explored to safeguard retinal ganglion cells (RGCs) from glaucoma-induced damage. The review also evaluates the potential of novel drug delivery systems, such as biodegradable implants and nanoparticles, to enhance treatment effectiveness and patient adherence. Additionally, it highlights the role of personalized medicine in identifying new biomarkers and customizing therapies based on individual genetic and environmental factors.
青光眼是不可逆性失明的主要原因,是眼科领域的一项重大挑战。本综述探讨了青光眼治疗的最新进展,重点关注创新药物和创新策略。虽然新药物为降低眼压提供了有前景的方法,但它们也带来了与疗效和副作用相关的挑战。除了降低眼压外,正在探索新兴的神经保护方法,以保护视网膜神经节细胞免受青光眼所致损伤。本综述还评估了新型药物递送系统(如可生物降解植入物和纳米颗粒)提高治疗效果和患者依从性的潜力。此外,它强调了个性化医疗在识别新生物标志物以及根据个体遗传和环境因素定制治疗方案方面的作用。